Pain News and Research

Latest Pain News and Research

Hypertonic solution effective in reducing inflammation

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation.

From The University of Manchester 21 Sep 2012

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Many children with ASD also experience anxiety, GI problems and atypical sensory responses

One in 88 children has been diagnosed with an autism spectrum disorder (ASD) in the United States, according to the Centers for Disease Control and Prevention. A new study by a University of Missouri researcher found that many children with ASD also experience anxiety, chronic gastrointestinal (GI) problems and atypical sensory responses, which are heightened reactions to light, sound or particular textures.

20 Sep 2012

Hip implants are more likely to fail in obese people due to thigh size

University of Iowa researchers have determined that thigh size in obese people is a reason their hip implants are more likely to fail.

20 Sep 2012

Endothelial colony-forming cells show promise against inflammatory bowel disease

New research shows that a special population of stem cells found in cord blood has the innate ability to migrate to the intestine and contribute to the cell population there, suggesting the cells' potential to treat inflammatory bowel disease (IBD).

20 Sep 2012

Oral contraceptive use can lead to increased pain during intercourse among young women

According to the Guttmacher Institute, over ten million women in the US use oral contraceptives. Although birth control pills are an effective way to prevent pregnancy, keep acne at bay, and treat menstrual pain or irregularity, there may be some health concerns that are undisclosed to patients. A recent study suggests that oral contraceptive use can lead to increased pain during intercourse, with decreased libido and spontaneous arousability as well as diminished frequency of sexual intercourse and orgasm in young women.

19 Sep 2012

Inhaled pain relief effective in first labor stage

A Cochrane review shows that inhaled pain relief is more effective than no pain relief at all in reducing pain intensity during the first stage of labor, say researchers.

19 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

‘Disappointing’ findings for spinal manipulative therapy

Spinal manipulative therapy for acute low-back pain appears to be no better than other existing therapies for reducing pain and improving functional status, show the findings of a Cochrane review.

18 Sep 2012

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.

17 Sep 2012

Limited positive effect of Tafamidis in neurological disorders

Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults.

17 Sep 2012

Researchers investigate African plants effective in treating snakebite

A PhD student at the University of Copenhagen has drawn on nature's own pharmacy to help improve the treatment of snakebites in Africa.

17 Sep 2012

MIT engineers use ultrasound waves to enhance permeability of skin to drugs

Using ultrasound waves, MIT engineers have found a way to enhance the permeability of skin to drugs, making transdermal drug delivery more efficient. This technology could pave the way for noninvasive drug delivery or needle-free vaccinations, according to the researchers.

15 Sep 2012

Roundup: Calif. to probe hospital/doctor consolidations; Cuccinelli warns Va. health board on abortion clinic rules

California's attorney general has launched a broad investigation into whether growing consolidation among hospitals and doctor groups is pushing up the price of medical care, reflecting increasing scrutiny by antitrust regulators of medical-provider deals.

15 Sep 2012

FDA approves Lannett’s ANDA for Butalbital, Acetaminophen and Caffeine Tablets

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Butalbital, Acetaminophen and Caffeine Tablets, USP, 50mg/325mg/40mg.

15 Sep 2012

Severe egg allergy treatment shows promise

Specific oral tolerance induction with raw hen’s egg can reduce the severity of egg allergy in affected children, show study findings.

14 Sep 2012

Objective response rate promising after crizotinib for NSCLC

More than half of the latest evaluated participants from the ongoing phase II PROFILE 1005 trial of crizotinib against ALK-positive advanced non-small-cell lung cancer, achieved an objective tumor response, report researchers.

14 Sep 2012

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.

14 Sep 2012